NanoViricides financials
$1.30−13.33%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Jun 30 | FY25 Jun 30 | FY24 Jun 30 | FY23 Jun 30 | FY22 Jun 30 | FY21 Jun 30 | FY20 Jun 30 | FY19 Jun 30 | FY18 Jun 30 | FY17 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$8.3M | -$9.6M | -$8.5M | -$8.9M | -$8.1M | -$8.7M | -$8.0M | -$8.7M | -$9.3M | -$9.6M |
| Net income | -$8.2M | -$9.5M | -$8.3M | -$8.6M | -$8.1M | -$8.8M | -$13.4M | -$8.4M | -$8.6M | -$10.3M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.41 | $-0.63 | $-0.70 | $-0.74 | $-0.70 | $-0.81 | $-2.39 | $-2.35 | $-2.64 | $-3.40 |
| EBITDA | -$7.8M | -$8.8M | -$7.8M | -$8.2M | -$7.4M | -$8.0M | -$7.3M | -$8.0M | -$8.6M | -$8.9M |
| Operating cash flow | -$7.7M | -$8.5M | -$6.3M | -$5.7M | -$5.9M | -$8.2M | -$6.7M | -$6.8M | -$7.8M | -$7.9M |
| Free cash flow | -$7.8M | -$8.5M | -$6.5M | -$5.8M | -$6.2M | -$8.5M | -$6.7M | -$6.9M | -$8.0M | -$8.1M |
| Diluted shares | 20.2M | 15.1M | 11.9M | 11.6M | 11.5M | 10.9M | 5.6M | 3.6M | 3.2M | 3.0M |
Balance sheet
| Period end | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.8M | $1.6M | $4.8M | $8.1M | $14.1M | $20.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $94.8K | $95.3K |
| Total assets | $9.9M | $8.8M | $12.8M | $16.9M | $23.5M | $30.3M |
| Total liabilities | $1.2M | $1.3M | $1.4M | $2.0M | $412.8K | $351.1K |
| Shareholders' equity | $8.7M | $7.5M | $11.5M | $14.9M | $23.1M | $29.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology